Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 10 |
| List of Tables | 10 | 1 |
| List of Figures | 11 | 1 |
| Introduction | 12 | 1 |
| Global Markets Direct Report Coverage | 12 | 1 |
| Herpes Simplex Virus (HSV) Infections Overview | 13 | 1 |
| Therapeutics Development | 14 | 2 |
| Pipeline Products for Herpes Simplex Virus (HSV) Infections Overview | 14 | 1 |
| Pipeline Products for Herpes Simplex Virus (HSV) Infections Comparative Analysis | 15 | 1 |
| Herpes Simplex Virus (HSV) Infections Therapeutics under Development by Companies | 16 | 3 |
| Herpes Simplex Virus (HSV) Infections Therapeutics under Investigation by Universities/Institutes | 19 | 1 |
| Herpes Simplex Virus (HSV) Infections Pipeline Products Glance | 20 | 3 |
| Late Stage Products | 20 | 1 |
| Clinical Stage Products | 21 | 1 |
| Early Stage Products | 22 | 1 |
| Herpes Simplex Virus (HSV) Infections Products under Development by Companies | 23 | 3 |
| Herpes Simplex Virus (HSV) Infections Products under Investigation by Universities/Institutes | 26 | 1 |
| Herpes Simplex Virus (HSV) Infections Companies Involved in Therapeutics Development | 27 | 40 |
| Adamis Pharmaceuticals Corporation | 27 | 1 |
| Admedus Ltd | 28 | 1 |
| AiCuris GmbH &Co. KG | 29 | 1 |
| Almirall, S.A. | 30 | 1 |
| Astellas Pharma Inc. | 31 | 1 |
| Beech Tree Labs, Inc. | 32 | 1 |
| Beijing Minhai Biotechnology Co., Ltd | 33 | 1 |
| BioApex, s.r.o. | 34 | 1 |
| CEL-SCI Corporation | 35 | 1 |
| Editas Medicine, Inc. | 36 | 1 |
| Epiphany Biosciences, Inc. | 37 | 1 |
| Foamix Pharmaceuticals Ltd. | 38 | 1 |
| Genocea Biosciences, Inc. | 39 | 1 |
| GenVec, Inc. | 40 | 1 |
| Immune Design Corp. | 41 | 1 |
| Immunovaccine, Inc. | 42 | 1 |
| JN-International Medical Corporation | 43 | 1 |
| Microbiotix, Inc. | 44 | 1 |
| Mymetics Corporation | 45 | 1 |
| NanoBio Corporation | 46 | 1 |
| NanoViricides, Inc. | 47 | 1 |
| Onxeo SA | 48 | 1 |
| PaxVax, Inc. | 49 | 1 |
| Profectus BioSciences, Inc. | 50 | 1 |
| ReceptoPharm, Inc. | 51 | 1 |
| Redbiotec AG | 52 | 1 |
| Sanofi | 53 | 1 |
| Sanofi Pasteur SA | 54 | 1 |
| Savoy Pharmaceuticals, Inc. | 55 | 1 |
| Shulov Innovative Science Ltd. | 56 | 1 |
| Spider Biotech | 57 | 1 |
| Starpharma Holdings Limited | 58 | 1 |
| TGV-Laboratories | 59 | 1 |
| Tomegavax, Inc. | 60 | 1 |
| United BioPharma, Inc. | 61 | 1 |
| Vaccibody AS | 62 | 1 |
| Vaxart, Inc. | 63 | 1 |
| Vical Incorporated | 64 | 1 |
| Vironova AB | 65 | 1 |
| ViroStatics srl | 66 | 1 |
| Herpes Simplex Virus (HSV) Infections Therapeutics Assessment | 67 | 10 |
| Assessment by Monotherapy Products | 67 | 1 |
| Assessment by Combination Products | 68 | 1 |
| Assessment by Target | 69 | 2 |
| Assessment by Mechanism of Action | 71 | 2 |
| Assessment by Route of Administration | 73 | 2 |
| Assessment by Molecule Type | 75 | 2 |
| Drug Profiles | 77 | 69 |
| (carrageenan + MIV-150 + zinc acetate) - Drug Profile | 77 | 1 |
| Product Description | 77 | 1 |
| Mechanism of Action | 77 | 1 |
| R&D Progress | 77 | 2 |
| acyclovir - Drug Profile | 79 | 1 |
| Product Description | 79 | 1 |
| Mechanism of Action | 79 | 1 |
| R&D Progress | 79 | 1 |
| acyclovir - Drug Profile | 80 | 1 |
| Product Description | 80 | 1 |
| Mechanism of Action | 80 | 1 |
| R&D Progress | 80 | 1 |
| amenamevir - Drug Profile | 81 | 1 |
| Product Description | 81 | 1 |
| Mechanism of Action | 81 | 1 |
| R&D Progress | 81 | 1 |
| Aspidasept - Drug Profile | 82 | 1 |
| Product Description | 82 | 1 |
| Mechanism of Action | 82 | 1 |
| R&D Progress | 82 | 1 |
| astodrimer - Drug Profile | 83 | 1 |
| Product Description | 83 | 1 |
| Mechanism of Action | 83 | 1 |
| R&D Progress | 83 | 2 |
| B-220 - Drug Profile | 85 | 1 |
| Product Description | 85 | 1 |
| Mechanism of Action | 85 | 1 |
| R&D Progress | 85 | 1 |
| BA-368 - Drug Profile | 86 | 1 |
| Product Description | 86 | 1 |
| Mechanism of Action | 86 | 1 |
| R&D Progress | 86 | 1 |
| BTL-TMLHSV - Drug Profile | 87 | 1 |
| Product Description | 87 | 1 |
| Mechanism of Action | 87 | 1 |
| R&D Progress | 87 | 1 |
| C-31G - Drug Profile | 88 | 1 |
| Product Description | 88 | 1 |
| Mechanism of Action | 88 | 1 |
| R&D Progress | 88 | 2 |
| CEL-1000 - Drug Profile | 90 | 1 |
| Product Description | 90 | 1 |
| Mechanism of Action | 90 | 1 |
| R&D Progress | 90 | 2 |
| EBT-104 - Drug Profile | 92 | 1 |
| Product Description | 92 | 1 |
| Mechanism of Action | 92 | 1 |
| R&D Progress | 92 | 1 |
| FIT-039 - Drug Profile | 93 | 1 |
| Product Description | 93 | 1 |
| Mechanism of Action | 93 | 1 |
| R&D Progress | 93 | 1 |
| G-103 - Drug Profile | 94 | 1 |
| Product Description | 94 | 1 |
| Mechanism of Action | 94 | 1 |
| R&D Progress | 94 | 1 |
| GEN-002 - Drug Profile | 95 | 1 |
| Product Description | 95 | 1 |
| Mechanism of Action | 95 | 1 |
| R&D Progress | 95 | 1 |
| GEN-003 - Drug Profile | 96 | 1 |
| Product Description | 96 | 1 |
| Mechanism of Action | 96 | 1 |
| R&D Progress | 96 | 2 |
| Gene Therapy for HSV-1 Eye Infections - Drug Profile | 98 | 1 |
| Product Description | 98 | 1 |
| Mechanism of Action | 98 | 1 |
| R&D Progress | 98 | 1 |
| genital herpes (virus like particle) vaccine - Drug Profile | 99 | 1 |
| Product Description | 99 | 1 |
| Mechanism of Action | 99 | 1 |
| R&D Progress | 99 | 1 |
| genital herpes vaccine - Drug Profile | 100 | 1 |
| Product Description | 100 | 1 |
| Mechanism of Action | 100 | 1 |
| R&D Progress | 100 | 1 |
| genital herpes vaccine - Drug Profile | 101 | 1 |
| Product Description | 101 | 1 |
| Mechanism of Action | 101 | 1 |
| R&D Progress | 101 | 1 |
| genital herpes vaccine - Drug Profile | 102 | 1 |
| Product Description | 102 | 1 |
| Mechanism of Action | 102 | 1 |
| R&D Progress | 102 | 1 |
| genital herpes vaccine - Drug Profile | 103 | 1 |
| Product Description | 103 | 1 |
| Mechanism of Action | 103 | 1 |
| R&D Progress | 103 | 1 |
| GV-2207 - Drug Profile | 104 | 1 |
| Product Description | 104 | 1 |
| Mechanism of Action | 104 | 1 |
| R&D Progress | 104 | 1 |
| herpes simplex virus [type 1, 2] vaccine - Drug Profile | 105 | 1 |
| Product Description | 105 | 1 |
| Mechanism of Action | 105 | 1 |
| R&D Progress | 105 | 1 |
| herpes simplex virus [type 1, 2] vaccine - Drug Profile | 106 | 1 |
| Product Description | 106 | 1 |
| Mechanism of Action | 106 | 1 |
| R&D Progress | 106 | 1 |
| herpes simplex virus 1 vaccine - Drug Profile | 107 | 1 |
| Product Description | 107 | 1 |
| Mechanism of Action | 107 | 1 |
| R&D Progress | 107 | 1 |
| herpes simplex virus 2 vaccine - Drug Profile | 108 | 1 |
| Product Description | 108 | 1 |
| Mechanism of Action | 108 | 1 |
| R&D Progress | 108 | 1 |
| herpes simplex virus 2 vaccine - Drug Profile | 109 | 1 |
| Product Description | 109 | 1 |
| Mechanism of Action | 109 | 1 |
| R&D Progress | 109 | 1 |
| herpes simplex virus 2 vaccine - Drug Profile | 110 | 1 |
| Product Description | 110 | 1 |
| Mechanism of Action | 110 | 1 |
| R&D Progress | 110 | 1 |
| herpes simplex virus 2 vaccine - Drug Profile | 111 | 1 |
| Product Description | 111 | 1 |
| Mechanism of Action | 111 | 1 |
| R&D Progress | 111 | 1 |
| herpes simplex virus 2 vaccine - Drug Profile | 112 | 1 |
| Product Description | 112 | 1 |
| Mechanism of Action | 112 | 1 |
| R&D Progress | 112 | 1 |
| herpes simplex virus 2 vaccine - Drug Profile | 113 | 1 |
| Product Description | 113 | 1 |
| Mechanism of Action | 113 | 1 |
| R&D Progress | 113 | 1 |
| herpes simplex virus 2 vaccine - Drug Profile | 114 | 1 |
| Product Description | 114 | 1 |
| Mechanism of Action | 114 | 1 |
| R&D Progress | 114 | 1 |
| herpes simplex virus vaccine - Drug Profile | 115 | 1 |
| Product Description | 115 | 1 |
| Mechanism of Action | 115 | 1 |
| R&D Progress | 115 | 1 |
| HSV vaccine - Drug Profile | 116 | 1 |
| Product Description | 116 | 1 |
| Mechanism of Action | 116 | 1 |
| R&D Progress | 116 | 1 |
| HSV-529 - Drug Profile | 117 | 1 |
| Product Description | 117 | 1 |
| Mechanism of Action | 117 | 1 |
| R&D Progress | 117 | 2 |
| MB-66 - Drug Profile | 119 | 1 |
| Product Description | 119 | 1 |
| Mechanism of Action | 119 | 1 |
| R&D Progress | 119 | 1 |
| MBX-2168 - Drug Profile | 120 | 1 |
| Product Description | 120 | 1 |
| Mechanism of Action | 120 | 1 |
| R&D Progress | 120 | 1 |
| Monoclonal Antibody for Herpes Simplex Infections - Drug Profile | 121 | 1 |
| Product Description | 121 | 1 |
| Mechanism of Action | 121 | 1 |
| R&D Progress | 121 | 1 |
| Monoclonal Antibody for Herpes Simplex Infections - Drug Profile | 122 | 1 |
| Product Description | 122 | 1 |
| Mechanism of Action | 122 | 1 |
| R&D Progress | 122 | 1 |
| NAVI - Drug Profile | 123 | 1 |
| Product Description | 123 | 1 |
| Mechanism of Action | 123 | 1 |
| R&D Progress | 123 | 1 |
| Peptide for HIV and HSV Infections - Drug Profile | 124 | 1 |
| Product Description | 124 | 1 |
| Mechanism of Action | 124 | 1 |
| R&D Progress | 124 | 1 |
| pritelivir - Drug Profile | 125 | 1 |
| Product Description | 125 | 1 |
| Mechanism of Action | 125 | 1 |
| R&D Progress | 125 | 2 |
| RC-100b - Drug Profile | 127 | 1 |
| Product Description | 127 | 1 |
| Mechanism of Action | 127 | 1 |
| R&D Progress | 127 | 1 |
| RKP-00156 - Drug Profile | 128 | 1 |
| Product Description | 128 | 1 |
| Mechanism of Action | 128 | 1 |
| R&D Progress | 128 | 1 |
| RPI-78M - Drug Profile | 129 | 1 |
| Product Description | 129 | 1 |
| Mechanism of Action | 129 | 1 |
| R&D Progress | 129 | 2 |